ADC Reports EMA's Validation of MAA for Zynlonta to Treat R/R Diffuse Large B-Cell Lymphoma
- The MAA is based on the P-II LOTIS-2 study evaluating Zynlonta (CD19-directed ADC) in 145 patients with r/r DLBCL following two or more prior lines of systemic therapy
- The results demonstrated 48.3% ORR; 24.1% CR rate; 24.1% PR rate; patients had a median time to response of 1.3mos. & m-DoR was 13.4mos.
- With the validation, the EMA's CHMP will initiate the review process. Zynlonta has received the US FDA's approval for the treatment of r/r large B-cell lymphoma after two or more lines of systemic therapy including DLBCL & the therapy is also being evaluated as a therapeutic option in combination studies in other B-cell malignancies
to / article | Ref: Businesswire | Image: ADC
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at firstname.lastname@example.org